BioWorld looks at translational medicine, including: Engineering better bacterial backstabbers; Targeting bystander protein improves sepsis outcome; Long noncoding RNA has sex-specific role in depression; Targeted IL-12 heats up cold tumors; Fast route from fibroblasts to photoreceptors; Eating pro-inflammatory IgG helps prevent liver failure; Depression’s structural problem; Modeling the post-infarct heart; Interleukins rile each other up in reaction to implants; Complement links high BMI to dementia.

The largest study to date on hypermutated gliomas has delivered new insights into their origin, as well as their response to several different treatments. Specifically, even though they are hypermutated, such tumors are unlikely to respond to PD-1 blockers.

“Vaccines, obviously, are the ultimate solution for pandemics,” Rino Rappuoli told BioWorld. They have, he added, “already eliminated a lot of pandemic threats – smallpox, influenza, poliomyelitis.”

Specific therapies against a new disease take time to develop. But there are methods that can speed up that development.

“In any crisis, leaders have two equally important responsibilities: solve the immediate problem and keep it from happening again."

BioWorld looks at translational medicine, including: Exosomes deliver sepsis treatment; Dopamine has epigenetic role in addiction; Rejuvenating inflammation’s end; Gut repair with an iron will; Multiple drivers explained.

“Vaccines, obviously, are the ultimate solution for pandemics,” Rino Rappuoli told BioWorld. They have, he added, “already eliminated a lot of pandemic threats – smallpox, influenza, poliomyelitis.” And the road to normalcy from the current pandemic, or any pandemic, is likely to be open only once there is a vaccine.

Specific therapies against a new disease take time to develop. But there are methods that can speed up that development – and in the meantime, there are ways to make do with what’s already in the cupboard.

Tyto Care Ltd. nabbed $50 million in an oversubscribed round of funding the company will use to expand commercialization of its integrated telehealth platform and remote device with examination tools, which has seen a surge in demand with COVID-19. The new cash nearly doubles the New York-based company's total funding, bringing it to $105 million. Insight Partners, Olive Tree Ventures, and Qualcomm Ventures LLC led the latest round.